The FDA has awarded approval for what it says is its first drug for the treatment of multiple sclerosis (MS) in paediatric patients, giving the green light to Novartis’ Gilenya (fingolimod) specifically in relapsing forms of the disease following its designation as a Breakthrough Therapy last year.

 

Bron: Pharmafile | lees verder..